Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios
This program is supported by Amgen Inc, Autolus Limited, Syndax Pharmaceuticals, Inc, and Takeda Pharmaceuticals U.S.A., Inc.
3:00 p.m. - 6:00 p.m. Pacific time
ACCESS PROGRAM HERE
San Diego Convention Center
Room 30
On Demand program will be available here December 7, 2024.
Access Program Here
The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge in the field of ALL create practice and/or educational gaps, particularly for hematology-oncologists and oncology nurses who strive to deliver the best possible care to patients. This Medical Crossfire® will provide an ideal format for the leukemia care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into ALL treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.
Chair:
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center
Houston, TX
Speakers:
Hagop M. Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Houston, TX
Aaron C. Logan, MD, PhD
University of California San Francisco
San Francisco, CA
Rob Pieters, MD, PhD
Princess Máxima Center for Pediatric Oncology
Utrecht, Netherlands
Claire Roddie, MD, PhD
University College London Hospitals
London, United Kingdom
Ronald Viggiani
, Physicians' Education Resource
Email: rviggianimd@gmail.com